I used to be a heavy smoker and have tried to quit before. I've quit probably 5-6 times, each time around a week. I quit two weeks ago and this time my goal is permanent abstinence. I experienced the classic withdrawal symptoms in the first three days, and now after two weeks I'm getting lingering symptoms, mainly light depression and inability to concentrate.
I've heard that it takes two weeks for acetylcholine receptor levels to normalize after nicotine sensitization. But I don't know too much about the MAOI effects. The information I found seems contradictory though.
I found this article:
http://www.ncbi.nlm.nih.gov/entrez/...uids=11694206&query_hl=12&itool=pubmed_docsum
But wait a second...
http://www.ncbi.nlm.nih.gov/entrez/...uids=16177026&query_hl=15&itool=pubmed_docsum
Hmmmm....
http://www.ncbi.nlm.nih.gov/entrez/...uids=11343627&query_hl=15&itool=pubmed_DocSum
Can anybody shed some light on this?
I've heard that it takes two weeks for acetylcholine receptor levels to normalize after nicotine sensitization. But I don't know too much about the MAOI effects. The information I found seems contradictory though.
I found this article:
http://www.ncbi.nlm.nih.gov/entrez/...uids=11694206&query_hl=12&itool=pubmed_docsum
My interpretation of this is that I am still deficient in MAO-B activity. How does this square with my symptoms of depression and inattentiveness?"Platelet monoamine oxidase, smoking cessation, and tobacco withdrawal symptoms."
From ABSTRACT: Results showed that smoking behavior, indexed by expired air carbon monoxide levels, was negatively correlated with platelet MAO-B activity prior to smoking cessation. Moreover, MAO-B activity significantly increased by approximately 100% at 4 weeks after quitting smoking. However, little or no recovery occurred within the first week of abstinence, suggesting that the constituents in tobacco responsible for MAO inhibition may have half-lives of several days.
But wait a second...
http://www.ncbi.nlm.nih.gov/entrez/...uids=16177026&query_hl=15&itool=pubmed_docsum
I don't really understand these results. So nicotine is an MAOI, but MAO inhibition by another route actually increases the amount of self-administration of nicotine? Where is the causal relationship here?Monoamine oxidase inhibition dramatically increases the motivation to self-administer nicotine in rats.
Guillem K, Vouillac C, Azar MR, Parsons LH, Koob GF, Cador M, Stinus L.
Laboratoire de Neuropsychobiologie des Desadaptations, Unite Mixte de Recherche 5541, Centre National de la Recherche Scientifique, Universite de Bordeaux 2, 33076 Bordeaux Cedex, France.
Nicotine is the major neuroactive compound of tobacco, which has, by itself, weak reinforcing properties. It is known that levels of the enzymes monoamine oxidase A (MAO-A) and MAO-B are reduced in the platelets and brains of smokers and that substances, other than nicotine, present in tobacco smoke have MAO-inhibitory activities. Here, we report that inhibition of MAO dramatically and specifically increases the motivation to self-administer nicotine in rats. These effects were more prominent in rats selected for high responsiveness to novelty than in rats with low responsiveness to novelty. The results suggest that the inhibition of MAO activity by compounds present in tobacco smoke may combine with nicotine to produce the intense reinforcing properties of cigarette smoking that lead to addiction.
Hmmmm....
http://www.ncbi.nlm.nih.gov/entrez/...uids=11343627&query_hl=15&itool=pubmed_DocSum
Monoamine oxidases and tobacco smoking.
Berlin I, Anthenelli RM.
Department of Pharmacology, Pitie-Salpetriere University Hospital, Paris, France. [email protected]
Although nicotine has been identified as the main ingredient in tobacco responsible for aspects of the tobacco dependence syndrome, not all of the psychopharmacological effects of smoking can be explained by nicotine alone. Accumulating preclinical and clinical evidence has demonstrated that smoking also leads to potent inhibition of both types (A and B) of monoamine oxidase (MAO). Smokers have 30-40 % lower MAOB and 20-30 % lower MAOA activity than non-smokers. Reduced MAO activity in smokers has been shown by direct measures (platelets, positron emission tomographic studies) or by indirect measures (concentration of monoamine catabolites in plasma or CSF). We examine the hypothesis that chronic habitual smoking can be better understood in the context of two pharmacological factors: nicotine and reduced MAO activity. We speculate that MAO inhibition by compounds found in either tobacco or tobacco smoke can potentiate nicotine's effects. Based on this concept, more effective anti-smoking drug strategies may be developed. As a practical consequence of tobacco smoke's MAO-inhibitory properties, comparative psychiatric research studies need to screen and control for tobacco use.
Can anybody shed some light on this?